Background: Small molecules as shown by VX809 can rescue the mislocalization of F508del-CFTR. The aim of this study was to identify correctors with a clinical history and their targets of action.
Methods: CFTR correctors were screened using two F508del-CFTR expressing cell based HTS assays. Electrophysiological studies using CFBE41o(-) and HBE cells and in-vivo mouse assays confirmed CFTR rescue. The target of action was attained using pharmacological inhibitors and siRNA to specific genes.
Results: Ibuprofen was identified as a CFTR corrector. Ibuprofen treatment of polarized CFBE41o(-) monolayers increased the short-circuit current (Isc) response to stimulation. In vivo CF mice treatment with ibuprofen restored the CFTR trafficking. SiRNA knock down of cyclooxygenase expression caused partial F508del-CFTR correction.
Conclusion: These studies show that ibuprofen is a CFTR corrector and that it causes correction by COX-1 inhibition. Hence ibuprofen may be suitable to be part of a future CF combination therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcf.2014.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor on lipid metabolism in human bronchial epithelial cells.
Glycoconj J
January 2025
Department of Medical Biotechnology and Translational Medicine, University of Milano, Milan, Italy.
Cystic Fibrosis (CF) is a life-threatening hereditary disease resulting from mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that encodes a chloride channel essential for ion transport in epithelial cells. Mutations in CFTR, notably the prevalent F508del mutation, impair chloride transport, severely affecting the respiratory system and leading to recurrent infections. Recent therapeutic advancements include CFTR modulators such as ETI, a combination of two correctors (Elexacaftor and Tezacaftor) and a potentiator (Ivacaftor), that can improve CFTR function in patients with the F508del mutation.
View Article and Find Full Text PDFEfficacy of Cystic Fibrosis Transmembrane Regulator Corrector C17 in Beta-Sarcoglycanopathy-Assessment of Patient's Primary Myotubes.
Int J Mol Sci
December 2024
Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35131 Padova, Italy.
Limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4) is a rare disease that currently has no cure. It is caused by defects in the gene, mainly missense mutations, which cause the impairment of the sarcoglycan complex, membrane fragility, and progressive muscle degeneration. Here, we studied the fate of some β-sarcoglycan (β-SG) missense mutants, confirming that, like α-SG missense mutants, they are targeted for degradation through the ubiquitin-proteasome system.
View Article and Find Full Text PDFThe F508del-CFTR trafficking correctors elexacaftor and tezacaftor are CFTR-independent Ca-mobilizing agonists normalizing abnormal Ca levels in human airway epithelial cells.
Respir Res
December 2024
PRéTi, Université de Poitiers, Poitiers, France.
Background: Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) channel. For people with CF (pwCF) affected by the most common pathogenic variant F508del, a tritherapy, named Trikafta/Kaftrio (ETI: elexacaftor (VX-445) /tezacaftor (VX-661) / ivacaftor (VX-770)) was successfully developed. However, in CF airway epithelial cells the calcium homeostasis is also disturbed; it is observed an increased calcium mobilization in CF cells compared to non-CF cells.
View Article and Find Full Text PDFPharmacological rescue of the G85E CFTR variant by preclinical and approved modulators.
Front Pharmacol
November 2024
UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Article Synopsis
- * Researchers investigated the G85E-CFTR variant using human nasal epithelial cells and found that the drugs elexacaftor and tezacaftor modestly improved CFTR function, but chronic treatment with ivacaftor had negative effects.
- * The study suggests that combining elexacaftor with a new corrector, ARN23765, can significantly enhance CFTR activity and highlights the need for better drug combinations to help patients with the G85E mutation.
Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?
iScience
November 2024
CLINTEC, Karolinska Institutet NOVUM, Stockholm, Sweden.
Article Synopsis
- The introduction of modulators, correctors, and potentiators for the CFTR molecule has significantly improved the health of most individuals with cystic fibrosis (CF).
- While these therapies impact certain fatty acids, they do not address linoleic acid (LA) deficiency, which is linked to more severe forms of CF.
- The review examines lipid abnormalities in CF patients, such as altered phospholipid and cholesterol levels, and their connection to clinical symptoms, revealing these lipid issues can manifest before birth.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!